AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 31 min read$AUPH

TANG KEVIN purchased $2K of AUPH (indirect holdings)

TANG KEVIN (Chief Executive Officer) purchased 99 indirectly-held shares of Aurinia Pharmaceuticals Inc. (AUPH) at $15.34 on 2026-06-01.

Original reporting
SEC EDGAR · TANG KEVIN
Published Jun 3, 2026, 1:54 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 3, 2026, 2:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AUPH
Bullish
medium confidence
Mentioned
$AUPH
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AUPHBullishLow
01

Why it matters

The filing provides a new datapoint on insider behavior but does not include any new clinical, regulatory, or financial information that would reset valuation expectations.

02

Market read

Traders may treat as a minor positive sentiment input, but it is unlikely to be a standalone catalyst.

03

What to watch

The transaction value is ~$1.5k and may be statistically insignificant versus typical trading noise; absence of a 10b5-1 plan does not guarantee conviction.

Relevance 6/10Novelty 6/10Timing: Filed/posted after-hours on 2026-06-02 for a 2026-06-01 purchase

Background

This is an SEC Form 4 insider transaction disclosure (open-market purchase) by Aurinia Pharmaceuticals’ CEO/10% owner.

Company-level read

Ticker impact

$AUPHBullishMedium confidence
Context

Aurinia Pharmaceuticals CEO/10% owner filed an open-market purchase of 99 shares at $15.34 on 2026-06-01 (Form 4).

Expected impact

Likely limited near-term price impact; may slightly support sentiment rather than drive a move.

Evidence & confidence

Form 4 shows a small open-market buy by an executive; no 10b5-1 plan and no accompanying operational/clinical update is provided.

Market effects

Sector

Minimal; this is company-specific insider activity without sector-wide regulatory/clinical implications.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Small, routine insider buys can occur for diversification or personal liquidity needs and may not reflect a material change in outlook.

Key entities

  • issuer
    Aurinia Pharmaceuticals Inc.

    Subject of the insider transaction disclosure; CEO/10% owner purchased shares via open-market purchase.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AUPH insider trading history →

Related articles

SEP 17
$AUPHMed

Aurinia Stock Jumps After Earnings Beat And Pipeline Progress

Aurinia Pharmaceuticals reported Q2 revenue of $83.2M and net income of $37.4M, with LUPKYNIS sales at $79.4M. The company initiated new clinical studies for aritinercept. Analysts forecast revenue of $453.5M and earnings of $169.9M by 2029, with a 7% upside potential. The stock rose on earnings beat and pipeline progress.

simplywall.st2 min
SEP 16
$AUPHMed

Aurinia’s (AUPH) Profits Surge While Its One Drug Just Got Company

Aurinia Pharmaceuticals reported Q2 revenue of $83.2M, up 19%, and net income of $37.4M, up 74%. LUPKYNIS sales rose 19% to $79.4M. The company reiterated 2026 guidance and initiated a new Phase 4 study. R&D spending doubled, and tax expenses increased significantly. Cash reserves grew to $443.1M, despite a $74.9M share buyback.

yahoo.com2 min
AUG 21
$MRNAHighAI 9/10

After Moderna’s Big News, Here Are Three Biotechs to Watch

Moderna (MRNA) and Merck (MRK) rose sharply after positive Phase 3 trial data for a skin cancer therapy. Biotech sector, up 40% YTD, saw gains. Aurinia (AUPH) settled litigation with Teva (TEVA), removing uncertainty. Ocular (OCUL) received positive analyst ratings. Precigen (PGEN) reported strong Q2 revenue and expects cash flow breakeven by year-end.

pro.thestreet.com3 min
AUG 20
$AUPHMed

Aurinia Pharmaceuticals (AUPH) Secures Patent Settlement With Teva, Blocking Lupkynis Generic Until 2036

Aurinia Pharmaceuticals (AUPH) settled a patent dispute with Teva (TEVA), delaying a generic version of Lupkynis until 2036. The deal boosted AUPH shares by 7%. Aurinia also settled with Sun Pharma in 2023 and faces ongoing litigation with other generics makers. Lupkynis is Aurinia's sole marketed drug, with H1 2026 revenue up 21% YoY to $161M, and full-year guidance of $315M-$325M.

londoninsider.co.uk2 min
AUG 20
$AUPHMed

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

Aurinia Pharmaceuticals settled patent litigation with Teva, pushing back potential generic competition for voclosporin until 2036. Aurinia's stock rose 6% on the news. Lupkynis, Aurinia's voclosporin product, recorded $153M in sales in H1 2026, up 21% YoY. Aurinia's patent litigation with other companies continues.

zacks.com2 min